$INCANNEX HEALTHCARE LTD(IXHL)$ This is very important news, and it is one of the BEST pieces of clinical news IXHL has released in a long time.
Let me break it down carefully and simply for you:
⭐ 1. Phase 2 data CONFIRMS the drug actually works
This line is HUGE:
“IHL-42X showed up to an 83% reduction in AHI in Phase 2 trials.”
AHI = the number of times your breathing stops per hour.
👉 83% improvement is extremely strong.
👉 This means many patients had almost normal breathing during sleep.
This is NOT small improvement.
This is life-changing level improvement.
For sleep apnea patients, this is VERY meaningful.
---
⭐ 2. This makes IHL-42X one of the most promising oral treatments in the world
Today, sleep apnea treatment options are mostly:
CPAP (hard to tolerate)
Surgery (risky)
Devices (Expensive)
Weight loss (slow)
There is no FDA-approved simple oral pill that solves the problem.
If Incannex succeeds → they become first-in-class, which means:
🔥 Billion-dollar commercial opportunity
🔥 Massive buyout potential
🔥 Unique position in the market
This news strengthens their scientific credibility.
---
⭐ 3. The company has at least 12 months of cash runway
The news says:
“Cash of $73.3M, supports at least 12 months of financial runway.”
This is very important because:
It means the company will NOT die soon.
It means clinical progress continues.
It reduces near-term dilution fears.
Investors like companies with cash → no panic selling.
This is a stabilizing factor for the share.
⭐ 4. Anxiety drug PSX-001 also showed meaningful results
Not as big as IHL-42X, but still positive.
It shows the company has multiple working programs, not just one.
This reduces risk for investors.
Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
